|
Originally published In Press as doi:10.1074/jbc.M502143200 on May 11, 2005
J. Biol. Chem., Vol. 280, Issue 27, 25754-25759, July 8, 2005
The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice*
John D. Fryer,a
Ronald B. DeMattos,b
Lynn M. McCormick,c
Mark A. O'Dell,a
Michael L. Spinner,a
Kelly R. Bales,b
Steven M. Paul,bde
Patrick M. Sullivan,f
Maia Parsadanian,a
Guojun Bu,cg and
David M. Holtzmanahij
From the
Departments of aNeurology,h
Molecular Biology and Pharmacology,c
Pediatrics, and gCell Biology
and Physiology and iHope Center for Neurological
Disorders, Washington University School of Medicine, St. Louis, Missouri
63110, bNeuroscience Discovery Research, Eli Lilly and
Co., Lilly Research Laboratories, Indianapolis, Indiana 46285, Departments ofd
Pharmacology and Toxicology ande
Psychiatry, Indiana University School of Medicine,
Indianapolis, Indiana 46285, and fBryan Alzheimer's
Disease Research Center and Division of Neurology, Department of Medicine,
Duke University, Medical Center, Durham, North Carolina 27710
Apolipoprotein E (apoE), a chaperone for the amyloid (A )
peptide, regulates the deposition and structure of A that deposits in
the brain in Alzheimer disease (AD). The primary apoE receptor that regulates
levels of apoE in the brain is unknown. We report that the low density
lipoprotein receptor (LDLR) regulates the cellular uptake and central nervous
system levels of astrocyte-derived apoE. Cells lacking LDLR were unable to
appreciably endocytose astrocyte-secreted apoE-containing lipoprotein
particles. Moreover, cells overexpressing LDLR showed a dramatic increase in
apoE endocytosis and degradation. We also found that LDLR knock-out
(Ldlr-/-) mice had a significant, 50% increase in the
level of apoE in the cerebrospinal fluid and extracellular pools of the brain.
However, when the PDAPP mouse model of AD was bred onto an
Ldlr-/- background, we did not observe a significant
change in brain A levels either before or after the onset of A
deposition. Interestingly, human APOE3 or APOE4 (but not
APOE2) knock-in mice bred on an Ldlr-/-
background had a 210% and 380% increase, respectively, in the level of apoE in
cerebrospinal fluid. These results demonstrate that central nervous system
levels of both human and murine apoE are directly regulated by LDLR. Although
the increase in murine apoE caused by LDLR deficiency was not sufficient to
affect A levels or deposition by 10 months of age in PDAPP mice, it
remains a possibility that the increase in human apoE3 and apoE4 levels caused
by LDLR deficiency will affect this process and could hold promise for
therapeutic targets in AD.
Received for publication, February 24, 2005
, and in revised form, April 25, 2005.
* This work was supported by National Institutes of Health Grants AG13956,
P50 AG05681, and AG11355; MetLife Foundation; and Eli Lilly and Co. The costs
of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
j
To whom correspondence should be addressed: Dept. of Neurology, Campus Box
8111, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-9872; Fax:
314-362-2826; E-mail:
holtzman{at}wustl.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Yamada, T. Hashimoto, C. Yabuki, Y. Nagae, M. Tachikawa, D. K. Strickland, Q. Liu, G. Bu, J. M. Basak, D. M. Holtzman, et al.
The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid {beta} Peptides in an in Vitro Model of the Blood-Brain Barrier Cells
J. Biol. Chem.,
December 12, 2008;
283(50):
34554 - 34562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zou, R. K. Gopalraj, J. Lok, H. Zhu, I-F. Ling, J. F. Simpson, H. M. Tucker, J. F. Kelly, S. G. Younkin, D. W. Dickson, et al.
Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease
Hum. Mol. Genet.,
April 1, 2008;
17(7):
929 - 935.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M.M. Wilhelmus, I. Otte-Holler, J. J.J. van Triel, R. Veerhuis, M. L.C. Maat-Schieman, G. Bu, R. M.W. de Waal, and M. M. Verbeek
Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- -Mediated Cell Death of Cerebrovascular Cells
Am. J. Pathol.,
December 1, 2007;
171(6):
1989 - 1999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Van Dooren, D. Muyllaert, P. Borghgraef, A. Cresens, H. Devijver, I. Van der Auwera, S. Wera, I. Dewachter, and F. Van Leuven
Neuronal or Glial Expression of Human Apolipoprotein E4 Affects Parenchymal and Vascular Amyloid Pathology Differentially in Different Brain Regions of Double- and Triple-Transgenic Mice
Am. J. Pathol.,
January 1, 2006;
168(1):
245 - 260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Wahrle, H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman
Deletion of Abca1 Increases Abeta Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
J. Biol. Chem.,
December 30, 2005;
280(52):
43236 - 43242.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|